Peptide mapping for biopharmaceutical characterization: LC-MS/MS workflows, PTM analysis, and ICH Q6B compliance

Structural complexity is one of the defining challenges of biopharmaceutical development. Unlike small-molecule drugs, large protein therapeutics (monoclonal antibodies, fusion proteins, peptide therapeutics, and biosimilars) are heterogeneous by nature, subject to a wide range of post-translational modifications that can influence efficacy, safety, and stability in ways that bulk analytical techniques cannot resolve. Peptide mapping has become the gold standard analytical approach for addressing this complexity. It converts a protein into a defined set of peptides that can be individually identified, located within the primary sequence, and quantitatively monitored for site-specific modifications. Across the biopharmaceutical development lifecycle, from early characterization to regulatory submission, it has become an indispensable structural characterization tool.

What is peptide mapping, and how does it reveal a biopharmaceutical’s structural identity

Peptide mapping biopharmaceutical applications are grounded in the following principle: proteins are enzymatically digested into smaller peptides. Then, the peptide mixture is separated by liquid chromatography and analyzed by high‑resolution mass spectrometry (LC‑MS/MS). Matching observed peptide masses and fragment spectra to the expected sequence gives sequence coverage and confirms primary structure. Each detected peptide carries information about the region of the protein it originated from, whether it carries any modifications, and at what relative abundance those modifications occur.

This site-specific resolution is what sets peptide mapping LC-MS/MS apart from profile-based methods like ion-exchange chromatography or size exclusion chromatography, which measure only the aggregate effect of modifications on a chromatographic peak. For routine identity testing, peptide maps verify that the expressed protein matches the intended sequence and that modification patterns remain consistent across lots, both critical requirements for regulatory filings and comparability studies.

Peptide mapping-based multi-attribute methods monitor multiple site-specific Critical Quality Attributes (CQAs) in a single analytical run. Non-reduced maps define native disulfide bond formation and are optimized to avoid artificial scrambling that would misrepresent true structure. Data processing, while substantially automated, still requires expert review to prevent software-driven misassignments that could falsely suggest sequence variants or modification levels not present in the actual product.

From protein digestion to sequence coverage: building a robust peptide mapping workflow

The peptide mapping workflow steps that generate reliable, regulatory-grade data involve several interconnected decisions, each of which influences the quality and completeness of the final result.

Protein digestion trypsin peptide mapping has been the standard approach for decades, but standard denaturation–reduction–alkylation–desalting–trypsin protocols are labor-intensive and can introduce artificial modifications (primarily deamidation and oxidation) that complicate data interpretation. In regions of high cleavage density, fragments can be too small and hydrophilic to be retained on reversed-phase supports; in hydrophobic stretches lacking cleavage sites, peptides may be too large to detect. Both scenarios create blind spots in sequence coverage biopharmaceutical analysis that require deliberate mitigation.

Several strategies address these limitations:

Lys-C as an alternative protease retains activity under denaturing conditions, eliminating the desalting step and reducing preparation time. Digestion at neutral pH with methionine as a scavenger minimizes process-induced deamidation and oxidation, preserving the integrity of the final peptide map.
Dual protease digestion combining trypsin with chymotrypsin resolves hydrophobic stretches where trypsin alone falls short, achieving full coverage of sequences that would otherwise remain uncharacterized.
Automated digestion using immobilized enzyme systems prevents autolysis, controls digestion time precisely, and reduces analyst-to-analyst variability, a prerequisite for GMP-compatible peptide mapping protocols.
Column chemistry, including C4 over C18 for hydrophobic peptides, influences both retention and peak shape across the chromatographic run.

Designing and validating these workflows for specific molecules and regulatory contexts requires both deep analytical expertise and platform flexibility that goes beyond what standard off-the-shelf methods can provide.

Peptide mapping in biosimilar development and comparability studies

Biosimilar comparability peptide mapping represents one of the most analytically demanding applications of the technique, because the standard of evidence required extends beyond characterization to quantitative demonstration of similarity at the molecular level.

Peptide mapping of mAb biosimilar and broader biotherapeutic comparability workflows typically proceed in two phases.

A discovery phase using full MS/MS acquisition characterizes the complete modification profile of the reference product, generating a peptide workbook that defines the retention time, accurate mass, and charge states of all monitored attributes.
A monitoring phase then applies that workbook to test samples, enabling targeted quantitation of predefined quality attributes alongside new peak detection, a function that flags any chromatographic feature in the test product not present in the reference. This non-targeted detection capability is particularly valuable when sequence variants, unexpected glycoforms, or modifications arising from different manufacturing conditions cannot be anticipated in advance.

Critically, the peptide mapping protocol must also be transferable across laboratories without loss of quantitative precision, a prerequisite when comparability data are generated across multiple sites or submitted to different regulatory agencies. Interlaboratory studies have demonstrated that automated, optimized digestion workflows can achieve consistent Post-Translational Modification (PTM) quantitation across independent sites, with inter-laboratory precision within acceptable limits for most CQAs. This reproducibility is what makes peptide mapping LC-MS/MS a credible foundation for the analytical comparability packages that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require in biosimilar development.

Peptide mapping as a lot release tool: structural confirmation and batch-to-batch consistency

The transition of peptide mapping from a characterization technique into a routine lot release testing biologics tool has accelerated significantly, driven by improvements in instrument robustness, automated peptide mapping software platforms, and increasing regulatory recognition that LC-MS-based methods offer superior sensitivity and specificity compared to the conventional assays they can replace.

Under ICH Q6B peptide mapping requirement guidance, confirmation of primary sequence and determination of post-translational modifications are explicitly listed as characterization requirements for biotechnological and biological products. The peptide map serves as a reference method for identity testing, and batch-to-batch consistency of biologics must be demonstrated through consistent chromatographic profiles and stable modification abundances across manufacturing runs.

In practice, a well-developed peptide mapping protocol generates quantitative data on the full spectrum of relevant modifications in a single analytical run:

Deamidation oxidation glycosylation detection, isomerization, succinimide formation, and C-terminal and N-terminal compositional variants are all measurable at site-specific resolution.
For monoclonal antibody characterization and other biologic formats, glycan profiling at N-glycosylation sites (including fucosylated, afucosylated, and high-mannose species) is achievable within the same workflow.

The benefits of peptide mapping drug development, therefore, extend across the full product lifecycle, from initial sequence confirmation through process development, comparability studies, and post-approval lifecycle management.

At AMSbiopharma, we provide peptide mapping services for biopharmaceutical characterization, biosimilar comparability, and regulatory submission support, using UHPLC-MS/MS platforms with both data-dependent and data-independent acquisition workflows. Our analytical team designs phase-appropriate peptide mapping protocols tailored to the specific sequence, modification profile, and regulatory context of each program.

By AMSbiopharma

References

European Medicines Agency. ICH Q6B: Specifications: test procedures and acceptance criteria for biotechnological/biological products [Internet]. Amsterdam: EMA; 1999 [cited 2026 Jun 8]. Available from: https://www.ema.europa.eu/en/ich-q6b-specifications-test-procedures-acceptance-criteria-biotechnological-biological-products-scientific-guideline

Jakes C, Millán-Martín S, Kristensen DB, et al. Enhancing Peptide Mapping Sequence Coverage Through an Automated Dual Protease Digest. LCGC Europe. 2023;36(7):246–254. doi: 10.56530/lcgc.eu.zq5389j9

Liu YD, Stepurska K, Legg K, et al. Automation streamlines peptide map preparation, analysis and reporting for biotherapeutic antibody characterization. Talanta. 2026;298:128959. doi: 10.1016/j.talanta.2025.128959

Millán-Martín S, Jakes C, Carillo S, Bones J. Multi-Attribute Method (MAM) Analytical Workflow for Biotherapeutic Protein Characterization from Process Development to QC. Curr Protoc. 2023 Nov;3(11):e927. doi: 10.1002/cpz1.927

Rathore AS, Sarin D, Bhattacharya S, Kumar S. Multi-attribute monitoring applications in biopharmaceutical analysis. J Chromatogr Open. 2024;6(100166):100166. doi: 10.1016/j.jcoa.2024.100166